Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas
Dow Jones
Sep 25
Shares of Ocugen ticked higher after its treatment for retinitis pigmentosa, or RP, a type of genetic eye disorder, got provisional approval and priority designation from regulators in the Bahamas.
The stock was up 2.9% to $1.03 in premarket trading on Friday. At Thursday's market close, shares were down 26% year to date.
Ocugen said it got the approval for OCU400 from the Larta Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs in the Bahamas.
The biotechnology company plans to treat the first RP patient with OCU400 within 90 days following full Larta approval.
OCU400 is currently in Phase 3 development, targeting a broad RP indication from early- to late-stage disease and pediatric to adult patients.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.